Shares of Aryx Therapeutics, the Fremont biopharmaceutical, got bombed Wednesday following news released late the day before that its latest clinical trial of tecafarin, its novel blood-clot treatment, failed to achieve better results than wafarin, a blood-thinner sold by Bristol- Myers Squibb that was developed six decades ago.
Ayrx’s stock ended the trading day falling Read the rest of this entry »
Aryx Therapeutics, the the Fremont biopharmaceutical whose shares were slammed last July when Procter & Gamble pulled out of a partnership in developing Aryx’s drug to treat chronic constipation and abdominal pain, filed its proxy today ahead of its May 20 annual meeting.
In February 2008 the board’s compensation committee established Read the rest of this entry »
Aryx Therapeutics, the Fremont biopharamaceutical whose shares were slammed last July when Procter & Gamble pulled out of a partnership in developing Aryx’s drug to treat chronic constipation and abdominal pain, said today that it had raised $21.6 million through a private placement of about 9.6 million shares, along with the sale of warrants good on a potential 2.9 million additional shares.
The purchase price for the new shares was pegged at Read the rest of this entry »
Subscribe via RSS all feeds - Tech feed - O'Brien feed - Docu-Drama feed - Pink Slip 2.0 feed
